The common pathogens causing bronchitis are respiratory syncytial virus, Influenza virus A and B, Parainfluenza, rhinovirus, and similar viruses. For the people with smoking habits and people involved in passive inhalation, both along with the ones having history in respiratory diseases such as asthma, cystic fibrosis, or bronchiectasis have a higher chance of developing chronic bronchitis. Exposure to toxic chemicals, pollutants such as ammonia and sulfur dioxide have a higher risk of developing chronic bronchitis. Often it is observed that, people having allergy problems to pollens, dusts also develop acute bronchitis.
Companies covered:
- Melinta Therapeutics
- Boehringer Ingelheim
- Dr. Reddy’s Laboratories Ltd
- GlaxoSmithKline Pharmaceuticals Limited
- Pfizer Inc.
- Sanofi Aventis
- AstraZeneca plc.
- Novartis AG.
Regions covered:
- North America (U.S., Canada, Mexico)
- Europe (France, Germany, UK, Italy, Spain, Rest of Europe)
- Asia-Pacific (Japan, China, India, Australia, South Korea, Rest of Asia-Pacific)
- LAMEA (Brazil, South Arabia, South Africa, Rest of LAMEA)
Rising cases of bronchitis and therapeutic treatments to favor market growth in North America
Bronchitis Market is a leading cause of death in the U.S. affecting 16million Americans. The American Lung Association goes further by stating as many as 24 million Americans were affected due to various lung impairments, with bronchitis affecting majority of the population among them in 2016. In U.S., women have a chronic bronchitis at almost double rate of men with 5.9 million women had been diagnosed with chronic bronchitis in past 12 months. North American region is expected to grow due to factors like rising incidence of bronchitis and an increasing habits of chain-smoking in the present generation. In the region, the United States holds the largest bronchitis treatment market share due to factors such as a growing number of geriatric populations, along with an increasing number of diseases as well as healthcare spending in the country and the availability of advanced healthcare infrastructure are few of the factors, which is anticipated to stimulate the demand in this region.
Key benefits of the report:
- This study presents the analytical depiction of the global bronchitis treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global bronchitis treatment market share.
- The current market is quantitatively analyzed from 2020 to 2027 to highlight the global bronchitis treatment market growth scenario.
0 Comments